atezolizumab based treatment | avelumab based treatment | anti-PD-(L)1 | Immune checkpoint association | ||||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | atezolizumab plus SoC | avelumab alone | avelumab plus pegylated liposomal doxorubicin | avelumab plus SoC | nivolumab based treatment | nivolumab plus ipilimumab |